Despite the therapeutic potential of HDAC inhibitors, there are several challenges associated with targeting HDACs. One major challenge is the selectivity of HDAC inhibitors, as non-specific inhibition can lead to off-target effects and toxicity. Additionally, the development of resistance to HDAC inhibitors is a significant concern. Therefore, ongoing research aims to develop more selective and potent HDAC inhibitors, as well as combination therapies to overcome resistance.
